Canavan disease: diagnosis and molecular analysis
- PMID: 10464621
- DOI: 10.1089/gte.1997.1.21
Canavan disease: diagnosis and molecular analysis
Abstract
Canavan disease, spongy degeneration of the brain, is an autosomal recessive disorder with increased prevalence among Ashkenazi Jews. The biochemical marker for this disease is increased levels of N-acetylaspartic acid, due to the defective enzyme, aspartoacylase. This discovery allowed for accurate diagnosis of the disease. The gene for aspartoacylase has been cloned and two mutations have been found to be responsible for Canavan disease among Ashkenazi Jewish patients in 98% of the cases. Molecular analysis of healthy Jewish individuals for these mutations has resulted in an unexpectedly high carrier frequency for Canavan disease among Jews. Therefore, carrier testing of the Jewish population is possible and indicated.
Similar articles
-
Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.Front Biosci. 2000 Mar 1;5:D307-11. doi: 10.2741/matalon. Front Biosci. 2000. PMID: 10704428 Review.
-
Canavan disease: from spongy degeneration to molecular analysis.J Pediatr. 1995 Oct;127(4):511-7. doi: 10.1016/s0022-3476(95)70105-2. J Pediatr. 1995. PMID: 7562269 Review.
-
Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population.Eur J Hum Genet. 2000 Jul;8(7):557-60. doi: 10.1038/sj.ejhg.5200477. Eur J Hum Genet. 2000. PMID: 10909858
-
The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.J Inherit Metab Dis. 1999 Jun;22(4):531-4. doi: 10.1023/a:1005512524957. J Inherit Metab Dis. 1999. PMID: 10407784
-
Frequency of a DNA polymorphism at position Y231 in the aspartoacylase gene and its impact on DNA-based carrier testing for Canavan disease in the Ashkenazi Jewish Population.Hum Mutat. 1998;Suppl 1:S161-2. doi: 10.1002/humu.1380110154. Hum Mutat. 1998. PMID: 9452075 No abstract available.
Cited by
-
Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.Hum Mutat. 2017 May;38(5):524-531. doi: 10.1002/humu.23181. Epub 2017 Feb 14. Hum Mutat. 2017. PMID: 28101991 Free PMC article.
-
Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.J Struct Funct Genomics. 2007 Sep;8(2-3):73-84. doi: 10.1007/s10969-007-9023-6. Epub 2007 Sep 6. J Struct Funct Genomics. 2007. PMID: 17786587 Review.
-
Biochemistry and molecular biology of Canavan disease.Neurochem Res. 1999 Apr;24(4):507-13. doi: 10.1023/a:1022531829100. Neurochem Res. 1999. PMID: 10227683 Review.
-
Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.J Mol Neurosci. 2000 Oct;15(2):61-9. doi: 10.1385/JMN:15:2:61. J Mol Neurosci. 2000. PMID: 11220786 Review.
-
Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):456-61. doi: 10.1073/pnas.0607817104. Epub 2006 Dec 28. Proc Natl Acad Sci U S A. 2007. PMID: 17194761 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical